Adlai Nortye Ltd. (ANL)
Healthcare
- Fundamental
- 2
- Sentiment
- 3
- Technical
- 2
Do Nothing: fundamentalScore is 2 (below required 3), avgDollarVolume20 is only $2.25M with recent 3-session regular dollar volume $0.94M, and mandatory RSI/ADX data failed to load, so no eligible bullish setup can be admitted.
Company overview
Adlai Nortye Ltd. is a clinical-stage biotechnology company focused on developing innovative pharmaceutical products. Its lead compound, AN2025, is in Phase III trials for treating head and neck squamous cell carcinomas. The company also has other compounds in various stages of clinical trials targeting different cancers.
Fundamental
weakAdlai Nortye is a speculative, cash-backed development-stage biotech with improved liquidity but high dependency on clinical outcomes and financing.
Adlai Nortye remains an unprofitable, clinical-stage biotech, so P/E and EV/EBITDA-style valuation is not very informative and profitability metrics are deeply negative. The main offset is liquidity: the August 2026 6-K reports cash of about $231.9M (current ratio ~9.5) after large 2026 equity financings, but the investment case is still dominated by clinical/regulatory execution and dilution risk rather than operating fundamentals.
Sentiment
fairSentiment is modestly constructive following recent operational updates, but media and retail engagement remain thin.
Near-term tone is modestly constructive on the back of the company’s Aug-14 H1 2026 results/operational-progress release (announced) and recent AN4035 clinical-trial clearance headlines, with the limited last-14d media sample reading positive (polarity_score ≈ +0.50). Baseline coverage (30–90d) was also positive (≈ +0.45 after filtering), implying a roughly stable-to-slightly-better delta, while legal/case searches surfaced no material actions (investigation analyzer failed text extraction, so confirmation is limited).
Technical
weakTechnical indicators are incomplete, and liquidity is below required levels, limiting actionable insights.
Price structure is constructive - ANL sits above SMA20/50/200 and EMA9/21, and derived MACD remains above zero - but the read is degraded because RSI14, ADX14, WMA9/21, DEMA14, TEMA14, StdDev20, and Williams %R failed to load. Liquidity also fails both the 20-day dollar-volume floor (~$2.25M vs $5M required) and the recent 3-session regular-session check (~$0.94M vs $1.5M required), and fundamentalScore is 2, so the technical score is capped at 2 and no bullish admission is allowed.
You’re looking at 2026-08-15 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.